Coming Soon
06/12/2024
Pfizer:
Cyclin' Through Innovation: Next Generation CDKs in HR+ MBC
- Welcome and Introduction
Soo Chin Lee - Challenges in frontline treatment of HR+ MBC
Soo Chin Lee - Mechanisms of resistance to CDK4/6 inhibition in HR+ MBC
Yoichi Naito - Innovation in CDK inhibition in HR+ MBC
Antonio Giordano - Q&A
07/12/2024
Johnson and Johnson International (Singapore) Pte Ltd:
Pioneering advances in EGFRm NSCLC therapy: Navigating the future of patient care
- Welcome and Introduction
Ross A. Soo - Overview of unmet needs in EGFRm advanced NSCLC in Asia
Ross A. Soo - Treatment advances in common EGFRm advanced NSCLC
Alexander I. Spira - The evolving treatment landscape for advanced NSCLC with EGFR exon20insertion mutations
Tony S.K. Mok - Panel discussion and Q&A
Ross A. Soo, Tony S.K. Mok, Alexander I. Spira - Close
Ross A. Soo
08/12/2024
Prova Education:
HER2+ advanced solid tumors: A fireside chat on harnessing molecular profiling to improve patient outcomes
- Welcome and introduction
Eric Van Cutsem - Molecular profiling in the era of tumor-agnostic approvals
David SP Tan - The molecular tumor board for tumor agnostic therapeutic approaches
David SP Tan - HER2 overexpression testing to guide therapy in advanced solid tumors
Kathleen N. Moore - Clinical trial evidence in HER2+ advanced solid tumors
Kathleen N. Moore - From podium to practice: Application and guidelines in HER2+ advanced solid tumors
James Chih-Hsin Yang - Team-based safety monitoring, prophylaxis, and management with HER2-directed therapy
James Chih-Hsin Yang - Our “message worth sharing” on HER2+ advanced solid tumors
Eric Van Cutsem - Audience question and answer session
Eric Van Cutsem